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The realization that immortalized cell lines 
cultured in 2D flasks do not fully reflect the 
in vivo behavior of an organ, is not a new 
concept; however, the ability to reconstruct 
organ complexity or maintain organ biop-
sies has not been available until recently [1]. 
In the last 20 years, lab-on-a-chip (LOAC) 
technology has become a reality, where the 
expertise from computer industry of fabricat-
ing microprocessors has been applied to the 
miniaturization of biological systems. Thus, 
microliter volumes of fluids can be accurately 
flowed over specific areas of a chip that can 
contain precisely patterned arrangements of 
cells, engineered tissue or patient biopsies. 
An important facet of this marriage of dis-
ciplines is that analytical systems can also 
be reduced to a similar scale so they too 
can be integrated onto the same platform 
where cells, spheroids or tissue biopsies are 
cultured [2], allowing accurate and precise 
determination of metabolites or biomarkers 
of interest on a miniature scale. So, although 
the number of cells or soluble analyte pro-
duced is low, the actual concentration within 
the device is sufficiently high for accurate 
and precise  determination.
Prior to 2012, the biomedical applications 
of LOAC resided mainly within academic 
research laboratories and much innovative 
work continues there; however, with the 
National Institute of Health’s partnership 
with the Defense Advanced Research Projects 
Agency and the US FDA there was a major 
acceleration and step change. The initial 
investment of $13 million, part of a $70 mil-
lion 5-year plan, supported 17 projects to both 
develop the technology for maintaining tis-
sue and reconstruct one or more organs. The 
principal aim of this initiative was to provide 
new models that could be used for screening 
drugs in a cost-effective manner and thereby 
reduce the high drop-out and overall drug 
pipeline costs [3]. An additional advantage 
of the organ-on-a-chip (OOAC) approach 
is that it has the potential to at least reduce 
and in some instances replace animal mod-
els. The UK’s National Centre for Replace-
ment, Refinement & Reduction of Animals 
in Research (NC3Rs) is one of the leading 
international scientific organizations sup-
porting the development of alternative tech-
nology platforms with this avowed aim while 
pioneering better science [4]. Over the past 
decade, the devices have become more robust 
and currently several pharmaceutical com-
panies are trialing devices [5]; also, there has 
been a drive to develop the LOAC approach 
to aid in stratifying patient responses to 
 various therapeutic interventions [6].
In this special issue, colleagues have 
provided reviews of various applications 
of OOAC including work on stem cells, 
spheroids and tissue biopsies; there is novel 
research using bespoke devices for maintain-
ing tumor biopsies as well as a user survey 
and two perspectives giving expert insight 
into the future of the OOAC field.
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First, the review by Zhang and colleagues focuses 
on the use of embryonic stem cells and reprogrammed 
human-induced pluripotent stem cells and how these 
cells can be differentiated on chip to form organs [7]. 
This article clearly highlights the complexity of in vivo 
tissues, with relatively minor treatments of scaffolds or 
polymers resulting in major differences in organ forma-
tion and function. Following logically from the genera-
tion of organs, the article by Rogal and colleagues has 
reviewed the multiorgan field which has developed sig-
nificantly since the big NIH-led investment in 2012 [8]. 
The approach that appears to have the most potential 
is the ‘mix-and-match’ model, where functional inde-
pendent organ units are joined in a serial arrangement 
so that for instance, a drug metabolized by an on-chip 
liver can be transferred to a target organ, such as lung 
cancer to assess toxicity, or alternatively to the gut or 
brain, to allow assessment of off-target affects. The 
review by Ugolini and colleagues clearly illustrates 
that the field of OOAC is not limited to oncology as 
they discuss conditions and devices capable of main-
taining cardiac cells and tissues [9]. Many similarities 
exist between the devices used by different research-
ers in terms of materials, channel sizes and flow rates; 
however, additional complexity is required when using 
cardiac tissue with a need for electrical stimulation 
and maintenance of tissue tension. The requirement to 
mimic the intrinsic complexity of in vivo cardiac tissue 
has in my opinion resulted in on-chip heart research 
falling a little behind that of the oncology applications.
The reviews herein highlight the potential use of 
OOAC devices by the pharmaceutical industry in drug 
development. The fourth article by Eva-Marie Dehne 
and colleagues entitled, “The ascendance of microphysio-
logical systems to solve the drug testing dilemma” looks at 
the topic from an industry perspective and importantly 
highlights the role that regulatory bodies play [10]; as 
any shift to a new technology will require full accep-
tance by a number of national and international bod-
ies [11]. The review particularly discusses how the 
microfluidic platforms address the ADME (absorp-
tion, distribution, metabolism and excretion) criteria 
that are core to the pharmacology community. Fur-
thermore, the article by Huang reports the results of a 
survey of scientists working in pharma and academia 
and discusses what is expected of OOAC devices, in 
terms of the level of complexity which is deemed essen-
tial and what is desirable [12]. Despite concerns about 
reliability of these devices, one highly encouraging 
message is the general willingness of researchers from 
pharma and academia to adopt new models.
The article by Van Gent and colleagues describes 
the use of organotypic cultures and focuses on how 
these can be used in a high-throughput setting for drug 
screening [13]. A key point this article makes is that tis-
sue slices are the best model of maintaining intratu-
moral heterogeneity and tumor–stromal interactions; 
also there is a significant benefit of being able to predict 
response in days/weeks that can then be used to inform 
clinical decisions. Another point that Van Gent makes 
is the need for standardization of approach, a point also 
highly relevant to regulatory bodies. The work by my 
own group has focused on the optimization of patient-
derived tissue maintained in reliable and robust micro-
fluidic devices for use in customizing therapy [14]. The 
paper first describes the modeling of fluid flow over 
the biopsy and ways of improving perfusion through 
modifications to the device, and secondly reports the 
importance of measuring cell viability as this is often 
not reflected in the tissue architecture.
Finally, this special edition contains two perspec-
tives from Alexander Mosig, a life scientist [15] and John 
Wikswo, a biological physicist [16]. Despite coming 
from very different backgrounds there is a great deal 
of commonality in their respective views; both high-
light that integration of systems is essential for effec-
tive replication of the in vivo environment and also 
acknowledge that this remains a challenge. Finally, 
John Wikswo said in an answer to the question “If 
you had unlimited funding, what would you do with 
it to further OOAC research?”, to which he replied “… 
What I would try to do is launch a program of intense 
characterization of the organs to try to understand the 
extent to which the in vitro cells on plastic and OOACs 
in humans and animal replicate real physiology”. I 
agree wholeheartedly that there needs to be a compari-
son of technologies to provide a rational basis on which 
researchers and end-users can select particular models.
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